Dupixent Keeps Sanofi At Forefront Of European Pharma Growth

Hints At Raised Forecast For Blockbuster

Sanofi is on a roll thanks to Dupixent and the blockbuster is providing breathing space even when some key pipeline assets are delayed.

Sanofi_Berlin
A forecast 14% rise in earnings per share in 2021 will put Sanofi among the top European big pharma performers. • Source: Alamy

More from Business

More from Scrip